RC
IKT icon

Rangeley Capital’s Inhibikase Therapeutics IKT Stock Holding History

Rangeley Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Buy
+220,000
New +$391K 0.36% 62

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rangeley Capital's IKT Position: Q1 2026 in Review

Rangeley Capital opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 220,000 shares worth $370K. The stake represents 0.36% of the portfolio and ranks #62 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Rangeley Capital held 220,000 shares of Inhibikase Therapeutics worth $370K as of Q1 2026.
  • Inhibikase Therapeutics was a new Rangeley Capital position in Q1 2026.
  • Inhibikase Therapeutics made up 0.36% of Rangeley Capital's portfolio in Q1 2026, its #62 holding.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.